Close Menu

NEW YORK – Natera said on Wednesday that it has launched a follow-on public offering of $250 million of shares of its common stock.

In a shelf registration statement filed with the US Securities and Exchange Commission, Natera said that at an assumed public offering price of $61.79 per share, the last reported sale price of its common stock on Sept. 8, it would be offering 4,045,962 shares of its common stock.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A survey by Nature finds that most researchers want scientific meetings to continue virtually or with a virtual component, even after the pandemic ends.

Bloomberg reports that the B.1.351 SARS-CoV-2 viral variant could prompt the formulation of better vaccines.

Certain blood proteins may be able to distinguish COVID-19 patients who will become critically ill from those who will not, the Atlanta Journal-Constitution reports.

In Genome Biology this week: algorithm to assess regulatory features, approach to integrate multiple single-cell RNA-seq datasets, and more.